US 11,857,575 B2
Mesenchymal stem cell-derived exosomes and their uses
Olga De La Rosa, Madrid (ES); Eleuterio Lombardo, Madrid (ES); Wilfried Dalemans, Leuven (BE); Javier Garcia Casado, Caceres (ES); Rebeca Blazquez Duran, Caceres (ES); and Francisco Miguel Sanchez Margallo, Caceres (ES)
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED, Osaka (JP)
Appl. No. 15/772,668
Filed by Takeda Pharmaceutical Company Limited, Osaka (JP)
PCT Filed Nov. 2, 2016, PCT No. PCT/EP2016/076462
§ 371(c)(1), (2) Date May 1, 2018,
PCT Pub. No. WO2017/076924, PCT Pub. Date May 11, 2017.
Application 15/772,668 is a continuation in part of application No. 14/929,578, filed on Nov. 2, 2015, abandoned.
Prior Publication US 2018/0318354 A1, Nov. 8, 2018
Int. Cl. A61K 35/02 (2015.01); A61K 9/127 (2006.01); A61K 9/50 (2006.01); C12N 15/62 (2006.01); A61P 29/00 (2006.01); A61P 37/06 (2006.01); A61K 45/06 (2006.01); A61K 35/35 (2015.01); A61K 31/519 (2006.01); A61K 31/4709 (2006.01); A61K 31/444 (2006.01); A61K 31/4439 (2006.01); A61K 31/5377 (2006.01); G01N 1/40 (2006.01); C12N 5/0775 (2010.01); A61K 35/12 (2015.01); A61K 35/28 (2015.01)
CPC A61K 35/28 (2013.01) [A61K 9/127 (2013.01); A61K 9/5068 (2013.01); A61K 31/444 (2013.01); A61K 31/4439 (2013.01); A61K 31/4709 (2013.01); A61K 31/519 (2013.01); A61K 31/5377 (2013.01); A61K 35/35 (2013.01); A61K 45/06 (2013.01); A61P 29/00 (2018.01); A61P 37/06 (2018.01); C12N 15/625 (2013.01); A61K 2035/122 (2013.01); A61K 2035/128 (2013.01); A61K 2300/00 (2013.01); C12N 5/0667 (2013.01); G01N 1/4077 (2013.01)] 5 Claims
 
1. A method of treating an immune-mediated inflammatory disease in a subject suffering from said disease, wherein the immune-mediated inflammatory disease is an inflammatory disease characterized by chronic inflammation and the immune-mediated inflammatory disease is selected from the group consisting of rheumatoid arthritis (RA), Inflammatory Bowel Disease (IBD), and Crohn's disease and wherein the method comprises administering to said subject a therapeutically effective amount of an isolated exosome population derived from MSCs, wherein the MSCs are adipose tissue-derived stem cells (ASCs) characterized in that:
the exosomes from said population comprise TSP-1.